Pfizer’s Non-COVID Surge Drives Growth | Business and Finance News

Pfizer’s Q2 earnings show resilience as the core business holds steady despite fading COVID demand, fueled by strong performances from acquired assets like Seagen and Biohaven, plus blockbuster drugs Eliquis and Padcev. Revenue hit $15 billion—beating estimates—and the company bumped up its full-year forecast and EPS outlook, signaling momentum beyond pandemic products. Analysts are closely watching how Pfizer sustains growth without COVID revenue, manages its dividend, and delivers on its pipeline, especially with late-stage cancer and obesity trials looming. The market is optimistic, but scrutiny remains high as Pfizer navigates cost-cutting, manufacturing efficiency, AI integration, and regulatory wins to fuel long-term success. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/cf8edf845ef0b119